DPP4 and COVID-19: Conversely, a meta-analysis done by Nguyen et al. (2022) has found that treatment with DPP-4 inhibitors increases the mortality among diabetics infected with COVID-19 (OR 1.23, 95% CI 1.07–1.42) [12].